Abstract
Macrophage (Mϕ) repolarization from a pro-tumor, immunosuppressive phenotype towards an anti-tumor, pro-inflammatory state represents a promising therapeutic strategy in patients with cancer1. Successful reprogramming of Mϕ in a clinical setting has not been documented. Here, we traced the evolution at single-cell resolution of a diffuse midline glioma (DMG) with H3K27M mutation which metastasized in the abdomen after placing a ventriculoperitoneal (VP) shunt and exploited this information for therapeutic decision-making. The primary tumor showed a complex cellular and genomic landscape characterized by heterogeneous cancer cells and a tumor-supportive immune microenvironment. Upon metastasis, malignant cells populated the peritoneum and triggered a massive anti-inflammatory immune cell infiltration and expansion of myeloid-derived suppressor cells (MDSCs) in peripheral blood. Hydroxychloroquine adjuvant treatment started to overcome the immunosuppressive milieu, which resulted in a decrease in peritoneal cancer cells and pro-tumor innate immune cells. Importantly, an emergence of anti-tumor, pro-inflammatory macrophages and cytotoxic T-cells was observed, accompanied by the activation of monocytes in the blood. Our study advocates the employment of single-cell technologies to better understand and inspire therapeutic regimens in patients with cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
C.R.M. is supported by the Princess Maxima Center and the European Unions Horizon 2020 Sklodowska-Curie Actions (project AiPBAND) under grant 76428. F.K. is supported by ZonMW-TOP project 91-21-6061. W.M. is supported by the Italian National Operational Programme on Research 2014-2020 (PON AIM 1859703-2). D.v.V and H.G.S. are supported by the Princess Maxima Center and Kika (Kinderen Kankervrij).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
To whom it may concern, Referring to our letter of 9 July 2021 (reference number RJ/21/500745) it is hereby confirmed that the Medical Research Ethics Committee METC Utrecht has waived the obligation for ethics review of the casestudy presented in the submitted manuscript, titled 'Reprogramming of pro-tumor macrophages by hydroxychloroquine in an abdominally metastasized diffuse midline glioma'. The committee refers to the Dutch Medical Research Involving Human Subjects Act (WMO) to substantiate this decision. Yours sincerely, on behalf of the Medical Research Ethics Committee, Department of Research Review
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data and filtered matrix files for the sn/scRNA-seq have been deposited as a series in the NCBI Gene Expression Omnibus under accession number GSE168548. All other data are available from the corresponding author upon reasonable request.
